A Form 4 filed on August 24, 2026 with the U.S. Securities and Exchange Commission discloses that Brad Hively, a director of Starling Oncology, Inc. (NASDAQ:STLN), sold 298,853 shares of common stock on August 21, 2026 pursuant to a Rule 10b5-1 trading plan.

Key Highlights

  • Shares sold: Brad Hively disposed of 298,853 shares of Starling Oncology common stock on August 21, 2026.
  • Weighted average price: Shares were sold at a weighted average price of $6.5126, with individual transaction prices ranging from $6.37 to $6.75 per share.
  • Remaining ownership: Following the transaction, Hively directly owns 411,976 shares of common stock.
  • Rule 10b5-1 plan: The filing indicates the transaction was made pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
  • Role: Hively is identified in the filing solely as a director of Starling Oncology, Inc.

Brad Hively's Share Sale at Starling Oncology: Transaction Details

According to the filing, Brad Hively sold 298,853 shares of Starling Oncology, Inc. common stock on August 21, 2026, with the disposition recorded under transaction code "S." The filing notes that the $6.5126 figure "represents a weighted average price" and that "these shares were sold in multiple transactions at prices ranging from $6.37 to $6.75 per share." Complete information on the number of shares sold at each price within the range is available upon request by the SEC, the issuer, or a stockholder of the issuer, as disclosed in the filing's footnote.

The Form 4 indicates the sale was made under a written plan consistent with Rule 10b5-1(c), as noted by the checkbox marked on the form. The filing was signed by Mark Hueppelsheuser as attorney-in-fact for Brad Hively and submitted on August 24, 2026. Following the reported transaction, Hively directly holds 411,976 shares of Starling Oncology common stock, according to the filing's Table I disclosure.

Hively is listed in the filing as a director of Starling Oncology, Inc., with an address listed care of the company at 18000 Studebaker Rd, Suite 800, Cerritos, California 90703. No derivative securities transactions were reported in Table II of the filing.

What Was Disclosed

The filing reports a single disposition of 298,853 shares of Starling Oncology common stock by director Brad Hively on August 21, 2026, at a weighted average price of $6.5126 per share, leaving him with 411,976 directly held shares.